Stem Cell Therapy for Multiple Sclerosis Market Report 2026

The stem cell therapy for multiple sclerosis market size has grown rapidly in recent years. It will grow from $1.82 billion in 2025 to $2.05 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to advancements in multiple sclerosis treatment research, increasing diagnosis rates of autoimmune disorders, expansion of stem cell clinical trials, improved patient selection protocols, growing availability of specialized neurology centers.

The stem cell therapy for multiple sclerosis market size is expected to see rapid growth in the next few years. It will grow to $3.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to increasing long-term efficacy data for stem cell therapies, rising demand for disease-modifying treatments, expansion of personalized neurology care, growing investments in neuro-regenerative research, increasing collaboration between hospitals and research institutes. Major trends in the forecast period include increasing adoption of autologous hematopoietic stem cell transplants, growing focus on immune system reset therapies, rising adoption of mesenchymal stem cell applications, increasing use of targeted delivery methods, enhanced clinical monitoring and outcome tracking.

The increasing prevalence of multiple sclerosis (MS) is expected to significantly drive the growth of the stem cell therapy for multiple sclerosis market. Multiple sclerosis is a chronic autoimmune condition that damages the protective myelin sheath surrounding nerve fibers in the central nervous system, disrupting communication between the brain and body and causing symptoms such as fatigue, muscle weakness, and vision problems. The rise in MS cases is primarily due to improved diagnostic capabilities, as advances in medical imaging and increased awareness allow for earlier and more accurate identification of the disease, resulting in higher reported prevalence. Stem cell therapy for multiple sclerosis supports the repair of damaged myelin, modulates abnormal immune responses, and promotes nerve cell regeneration, helping to reduce symptoms and potentially slow disease progression. For instance, in May 2024, the MS Trust, a UK-based organization, reported that approximately 2.9 million people worldwide live with multiple sclerosis, including over 150,000 individuals in the UK. Therefore, the rising prevalence of MS is expected to drive the expansion of the stem cell therapy for multiple sclerosis market.

Major companies in this market are focusing on innovations in autologous mesenchymal stem cell therapies, particularly using adipose-derived mesenchymal stem cells (ADMSCs), to enhance safety, efficacy, and regenerative outcomes for patients with relapsing-remitting and progressive MS. ADMSCs are multipotent stem cells derived from fat tissue that can differentiate into multiple cell types and offer regenerative and immunomodulatory benefits in autoimmune and neurodegenerative conditions. For instance, in August 2025, Hope Biosciences, LLC, a US-based biopharmaceutical company, introduced its HB-adMSCs therapy, delivering high-dose infusions of adipose-derived mesenchymal stem cells with repeat dosing over a 32-week period. This therapy combines immunomodulatory and neuroregenerative mechanisms, aiming to slow disease progression and repair myelin damage, offering an alternative to conventional immunosuppressive treatments.

In November 2024, Pluri Inc., an Israel-based biotechnology company, partnered with Brainstorm Cell Therapeutics Ltd. to advance regenerative therapies. This collaboration aims to accelerate the development and commercialization of innovative stem cell treatments for multiple sclerosis by combining Pluri Inc.’s expertise in stem cell technologies with Brainstorm Cell Therapeutics Ltd.’s clinical experience. Brainstorm Cell Therapeutics Ltd. is a US-based biotechnology company specializing in stem cell therapies for multiple sclerosis.

Major companies operating in the stem cell therapy for multiple sclerosis market are Sana Biotechnology Inc., Century Therapeutics Inc., Reelabs Private Limited, PlacidWay LLC, MedAccess Guarantee Ltd, Celltex Therapeutics Corporation, CELLTEX THERAPEUTICS CORP, BrainStorm Cell Therapeutics Ltd., Athersys Inc., Advancells Dermaceuticals Private Limited, ImStem Biotechnology Inc., NeuroGenesis Bio Inc., Stem Cell Medicine Ltd., Biotherapy International, R3 Stem Cell, Hope Biosciences LLC, FibroBiologics Inc., Global Institute of Stem Cell Therapy and Research Inc., ProgenCell, Stemwell.

North America was the largest region in the stem cell therapy for multiple sclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell therapy for multiple sclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stem cell therapy for multiple sclerosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the stem cell therapy for multiple sclerosis market by increasing costs of imported cell processing systems, infusion devices, advanced imaging tools, and laboratory consumables. Neurology centers and hospitals in North America and Europe are most affected due to reliance on imported specialized equipment, while Asia-Pacific faces higher costs in clinical trial execution. These tariffs are increasing treatment costs and extending adoption timelines. However, they are also supporting domestic manufacturing of medical devices, regional clinical research capabilities, and localized development of neuro-regenerative therapies.

The stem cell therapy for multiple sclerosis market research report is one of a series of new reports that provides stem cell therapy for multiple sclerosis market statistics, including stem cell therapy for multiple sclerosis industry global market size, regional shares, competitors with a stem cell therapy for multiple sclerosis market share, detailed stem cell therapy for multiple sclerosis market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell therapy for multiple sclerosis industry. This stem cell therapy for multiple sclerosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Stem cell therapy for multiple sclerosis is a regenerative medical approach that utilizes stem cells to repair nerve damage and restore immune system balance in patients with multiple sclerosis, an autoimmune disorder that attacks the protective myelin sheath around nerve fibers. The therapy aims to halt disease progression, reduce inflammation, and promote regeneration of damaged nervous tissue.

The main components of stem cell therapy for multiple sclerosis include embryonic stem cells, adult stem cells, induced pluripotent stem cells, mesenchymal stem cells, and hematopoietic stem cells. Therapy using embryonic stem cells involves transplanting pluripotent cells derived from early-stage embryos to repair damaged myelin and support neural regeneration. Treatment approaches include autologous and allogeneic stem cell therapies. Delivery methods include intravenous injection, intrathecal injection, and direct intraspinal administration. Applications cover relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), and progressive relapsing multiple sclerosis (PRMS). End users include hospitals, specialty clinics, research institutes, and others.

The stem cell therapy for multiple sclerosis market includes revenues earned by providing services such as stem cell collection and processing services, cryopreservation and storage services, patient preconditioning services, post-therapy rehabilitation services, and immune system profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.